<DOC>
	<DOCNO>NCT00036166</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy FK463 patient proven probable invasive infection due Aspergillus specie .</brief_summary>
	<brief_title>Study FK463 Treatment Invasive Aspergillosis</brief_title>
	<detailed_description>This open-label , non-comparative study intravenous FK463 . Enrollment include least 100 patient evaluable efficacy .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<criteria>Inclusion Criteria Has prove probable systemic infection Aspergillus specie Exclusion Criteria Has abnormal liver test parameter , e.g. , AST ALT &gt; 10 time upper limit normal Has bronchopulmonary aspergillosis , aspergillomas , sinus aspergillosis external otitis histologic evidence tissue invasion Has lifeexpectancy judge less 5 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Aspergillus</keyword>
	<keyword>Anti-Fungal</keyword>
</DOC>